JAZZ250117P130000
- 7.31
- -0.20-2.66%
Jazz Pharmaceuticals Newsroom
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $195
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $195
Jazz Pharmaceuticals (JAZZ) Gets a Buy From TD Cowen
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Acadia Healthcare (ACHC) and Genmab (GMAB)
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $163 to $230
Morgan Stanley Upgrades Jazz Pharmaceuticals to Overweight From Equalweight, $175 Price Target
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $179
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $163
Piper Sandler Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $207
RBC Capital Reiterates Outperform on Jazz Pharmaceuticals, Maintains $179 Price Target
Jazz Pharmaceuticals Analyst Ratings
RBC Capital Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $179
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $160 to $207
Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Analyst Ratings
TD Cowen Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Piper Sandler Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Cuts Target Price to $163